Kimberly-Clark and Kenvue merger model
Kimberly-Clark’s 2026 acquisition of Kenvue: shares, cash, synergies, leverage. Read a real stock-and-cash merger from its filings: price it at a fixed exchange ratio, fund the cash, rebuild earnings per share with and without the synergies, track leverage to the target, and say what the premium leaves for the buyer’s holders.
By Surojit Chakraverti, founder of L3VLUP and an investor running a long-short healthcare and technology equities strategy.
On this subject: kimberly-clark and kenvue merger model.Updated 20 November 2026
Who builds it, and for whatThe model an adviser, a credit analyst or a shareholder builds when a strategic buyer pays mostly in its own shares: the offer as a fixed exchange ratio and cash, the funding as the filings describe it, earnings per share against the buyer standalone, leverage against the stated target, and the synergy value against the premium. Built from the deal’s SEC filings, with every input they do not give labelled as an assumption.
Every sheet below, in your browser, with its outputs and checks
Starter workbook free with an account. Worked model: one a month with Plus, every one with Pro. Downloads
| A | B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|---|
| 1 | Assumptions | |||||||
| 2 | $m unless stated. Disclosed figures carry their source on the Sources sheet; the rest are illustrative inputs, labelled. | |||||||
| 4 | Driver | Unit | FY2027E | FY2028E | FY2029E | FY2030E | Notes | |
| 5 | Scenario | |||||||
| 6 | Scenario | # | 1 | 1 = base, 2 = downside, 3 = upside. Base: Kimberly-Clark management’s view of Kenvue and the disclosed synergies. Downside: half the synergies, a year later. Upside: Kenvue management’s own projections and the disclosed synergies. | ||||
| 8 | The merger agreement (2 November 2025) | |||||||
| 9 | Cash per Kenvue share | $ per share | 3.50 | Disclosed: the Cash Consideration (8-K of 3 November 2025, Item 1.01). | ||||
| 10 | Exchange ratio, Kimberly-Clark shares per 1,000 Kenvue shares | shares | 146.25 | Disclosed: 0.14625 of a Kimberly-Clark share for each Kenvue share, fixed, with no collar (8-K of 3 November 2025, Item 1.01). | ||||
| 11 | Kimberly-Clark share price used to value the stock | $ per share | 119.71 | Disclosed reference: the close on 31 October 2025, on which the announcement’s $21.01 and $48.7bn were struck (joint proxy, Background of the Mergers, p.72). The stock part floats with this price; the price at completion is not given in the documents read. | ||||
| 12 | Kenvue reference price for the premium | $ per share | 14.37 | Disclosed: Kenvue’s close on 31 October 2025, after the acetaminophen reports (joint proxy, p.72). Other readings the proxy gives: the 90-day volume-weighted average of $18.24, and $20.54 on 28 August 2025, the day of the first proposal. | ||||
| 13 | Kenvue 90-day volume-weighted average price to 31 October 2025 | $ per share | 18.24 | Disclosed (joint proxy, K-C board’s reasons, p.77). | ||||
| 14 | Kenvue shares outstanding at signing | m shares | 1,915.80 | Disclosed: 1,915.8 million at 30 October 2025, the figure in the merger agreement (joint proxy, pro forma note 4, p.181). | ||||
| 15 | Kenvue net debt at 28 September 2025 | $m | 7,834.0 | Disclosed: debt $8,973m less cash $1,139m (Kenvue 10-Q for the third quarter of 2025). The announcement’s enterprise value does not itemise its bridge. | ||||
| 16 | Enterprise value, as announced | $m | 48,700.0 | Disclosed: approximately $48.7bn (joint press release, 3 November 2025). | ||||
| 17 | EV / LTM adjusted EBITDA, as announced | x | 14.3x | Disclosed: approximately 14.3x, or 8.8x including the run-rate synergies (joint press release). | ||||
| 18 | EV / LTM adjusted EBITDA plus run-rate synergies, as announced | x | 8.8x | Disclosed (joint press release). | ||||
| 20 | Completion (2 November 2026) | |||||||
| 21 | Kimberly-Clark shares delivered to Kenvue holders | m shares | 281.06 | Disclosed: approximately 281,060,840 (Kimberly-Clark 8-K of 2 November 2026, Item 2.01). Converted equity awards are not counted. | ||||
| 22 | Kimberly-Clark shares outstanding before completion | m shares | 332.60 | Disclosed: at 30 September 2026 (Kimberly-Clark 10-Q for the third quarter of 2026). For ownership. | ||||
| 23 | Kimberly-Clark diluted shares, standalone | m shares | 333.70 | Disclosed: the diluted weighted average for the third quarter of 2026 (same 10-Q). Held flat: buybacks are not modelled, and the announcement limits them until leverage is back to about 2.0x. | ||||
| 25 | Funding the cash (October 2026) | |||||||
| 26 | 5.100% notes due 2028 | $m | 750.0 | Disclosed (Kimberly-Clark 8-K of 29 October 2026, Item 1.01). | ||||
| 27 | 5.300% notes due 2029 | $m | 1,000.0 | |||||
| 28 | 5.450% notes due 2031 | $m | 1,250.0 | |||||
| 29 | 5.650% notes due 2034 | $m | 750.0 | |||||
| 30 | 5.800% notes due 2036 | $m | 1,150.0 | |||||
| 31 | Coupon, 2028 notes | % | 5.1% | |||||
| 32 | Coupon, 2029 notes | % | 5.3% | |||||
| 33 | Coupon, 2031 notes | % | 5.5% | |||||
| 34 | Coupon, 2034 notes | % | 5.7% | |||||
| 35 | Coupon, 2036 notes | % | 5.8% | |||||
| 36 | New senior notes | $m | 4,900.0 | $4.9bn, issued 29 October 2026 to fund the cash consideration and costs. | ||||
| 37 | Weighted coupon on the new notes | % | 5.5% | The forward-starting swaps settled at issue (10-Q, note 5) are left out. | ||||
| 38 | Commercial paper drawn at completion | $m | 1,000.0 | Disclosed: approximately $1.0bn (Kimberly-Clark 10-Q for the third quarter of 2026, note 12). | ||||
| 39 | Rate on commercial paper | % | 4.0% | Illustrative. Not disclosed. | ||||
| 40 | Interest forgone on cash used | % | 3.0% | Illustrative. | ||||
| 41 | Transaction costs paid at completion | $m | 309.0 | Disclosed estimates: Kimberly-Clark’s $259m of transaction expenses and $50m of retention bonuses at closing (joint proxy, pro forma notes 4f and 4g, p.183). Kenvue’s own costs are not disclosed. | ||||
| 43 | Balance sheets before completion | |||||||
| 44 | Kimberly-Clark debt, 30 September 2026 | $m | 6,491.0 | Disclosed: $621m within one year and $5,870m long-term (10-Q for the third quarter of 2026). | ||||
| 45 | Kimberly-Clark cash, 30 September 2026 | $m | 1,874.0 | Disclosed (same 10-Q). Includes the IFP joint venture proceeds of July 2026. | ||||
| 46 | Kenvue debt, 27 September 2026 | $m | 8,206.0 | Disclosed (Kenvue 10-Q for the third quarter of 2026). Assumed: $6.4bn of Kenvue’s notes were exchanged for Kimberly-Clark notes on 4 November 2026, and about $0.6bn stayed outstanding. | ||||
| 47 | Kenvue cash, 27 September 2026 | $m | 1,039.0 | Disclosed (same 10-Q). | ||||
| 48 | Kimberly-Clark interest expense, standalone | $m | 256.0 | FY2025 as reported (10-K), held flat. Illustrative as a forecast. | ||||
| 49 | Kenvue interest expense, standalone | $m | 430.0 | FY2025 as reported (Kenvue 10-K), held flat. Illustrative as a forecast. | ||||
| 50 | Rate on the change in net debt after completion | % | 5.0% | Illustrative. Applied to net debt above or below the level at completion. | ||||
| 52 | Tax and other earnings items | |||||||
| 53 | Kimberly-Clark tax rate, applied to the deal adjustments | % | 22.8% | Disclosed: the FY2025 adjusted effective tax rate (10-K). Illustrative as a forecast. | ||||
| 54 | Kenvue tax rate, standalone | % | 26.5% | Derived: FY2025 tax of $529m on pre-tax income of $1,999m (Kenvue 10-K). Illustrative as a forecast. | ||||
| 55 | Kimberly-Clark depreciation and amortisation, % of revenue | % | 4.9% | Derived: FY2025 $805m on revenue of $16,447m (10-K). Illustrative as a forecast. | ||||
| 56 | Kenvue depreciation, % of revenue | % | 2.0% | Derived: FY2025 depreciation and amortisation of $557m less amortisation of $257m, on revenue of $15,124m (Kenvue 10-K). Kenvue’s own amortisation is replaced by the purchase accounting below. | ||||
| 57 | Kimberly-Clark share of net income of equity companies | $m | 196.0 | FY2025 as reported (10-K), held flat. The IFP joint venture’s share from July 2026 is not added. | ||||
| 58 | Amortisation of acquired intangibles, a year | $m | 335.0 | Disclosed, preliminary: $136m on $1,352m of brands over 10 years and $199m on $2,992m of customer relationships over 15 years; $30,275m of brands are indefinite-lived and not amortised (joint proxy, pro forma notes 4c and 4bb, pp.183 to 185). | ||||
| 59 | Purchase accounting amortisation in earnings per share | # | 1 | 1 = included, 0 = excluded. Whether the combined company’s adjusted earnings exclude it is not disclosed. | ||||
| 60 | Dividend per share, combined company | $ per share | 5.12 | Disclosed rate: $1.28 a quarter in 2026 (10-Q), annualised and held flat. Illustrative as a forecast. Paid on every share after completion. | ||||
| 62 | Kimberly-Clark standalone projections (Kimberly-Clark management) | |||||||
| 63 | Revenue | $m | 17,427.0 | 17,931.0 | 18,459.0 | 19,013.0 | Disclosed (joint proxy, K-C standalone projections, pp.118 to 119). | |
| 64 | Adjusted EBITDA | $m | 4,003.0 | 4,325.0 | 4,452.0 | 4,586.0 | Disclosed (same table). | |
| 65 | Unlevered free cash flow | $m | 1,933.0 | 2,299.0 | 2,389.0 | 2,494.0 | Disclosed (same table). | |
| 67 | Kenvue projections, two views | |||||||
| 68 | Revenue, as adjusted by Kimberly-Clark management | $m | 15,678.0 | 16,133.0 | 16,694.0 | 17,291.0 | Disclosed (joint proxy, K-C management adjusted Kenvue projections, p.120): slower growth, more marketing and R&D, savings later. | |
| 69 | Adjusted EBITDA, as adjusted by Kimberly-Clark management | $m | 3,414.0 | 3,547.0 | 3,816.0 | 4,077.0 | ||
| 70 | Unlevered free cash flow, as adjusted by Kimberly-Clark management | $m | 2,186.0 | 2,326.0 | 2,533.0 | 2,633.0 | ||
| 71 | Revenue, Kenvue management | $m | 15,913.0 | 16,500.0 | 17,154.0 | 17,847.0 | Disclosed (joint proxy, Kenvue standalone projections, pp.119 to 120). | |
| 72 | Adjusted EBITDA, Kenvue management | $m | 3,852.0 | 4,198.0 | 4,576.0 | 4,911.0 | ||
| 73 | Unlevered free cash flow, Kenvue management | $m | 2,515.0 | 2,815.0 | 3,103.0 | 3,256.0 | ||
| 74 | Revenue, selected scenario | $m | 15,678.0 | 16,133.0 | 16,694.0 | 17,291.0 | ||
| 75 | Adjusted EBITDA, selected scenario | $m | 3,414.0 | 3,547.0 | 3,816.0 | 4,077.0 | ||
| 76 | Unlevered free cash flow, selected scenario | $m | 2,186.0 | 2,326.0 | 2,533.0 | 2,633.0 | ||
| 78 | Synergies (joint proxy, synergy projections, p.121) | |||||||
| 79 | Run-rate cost synergies, EBITDA | $m | 1,893.0 | Disclosed: $1,893m a year from the third year (the announcement: approximately $1.9bn, in three years). | ||||
| 80 | Run-rate growth synergies, EBITDA, net of reinvestment | $m | 216.0 | Disclosed: $216m a year from the fourth year (the announcement: about $500m of profit from revenue synergies less about $300m reinvested). | ||||
| 81 | Cost synergies, % of run-rate, base and upside | % | 40.0% | 80.0% | 100.0% | 100.0% | Disclosed profile: $757m, $1,514m, then $1,893m. Read as years after completion, a choice of this page. | |
| 82 | Cost synergies, % of run-rate, downside | % | 0.0% | 40.0% | 80.0% | 100.0% | Illustrative: the disclosed profile a year later. | |
| 83 | Cost synergies, % of run-rate, selected scenario | % | 40.0% | 80.0% | 100.0% | 100.0% | ||
| 84 | Growth synergies, % of run-rate, base and upside | % | 25.0% | 50.0% | 75.0% | 100.0% | Disclosed profile: $54m, $108m, $162m, then $216m. | |
| 85 | Growth synergies, % of run-rate, downside | % | 0.0% | 25.0% | 50.0% | 75.0% | Illustrative: the disclosed profile a year later. | |
| 86 | Growth synergies, % of run-rate, selected scenario | % | 25.0% | 50.0% | 75.0% | 100.0% | ||
| 87 | Synergies realised, % of disclosed, base and upside | % | 100.0% | Illustrative. The disclosed estimates in full. | ||||
| 88 | Synergies realised, % of disclosed, downside | % | 50.0% | Illustrative. | ||||
| 89 | Synergies realised, selected scenario | % | 100.0% | |||||
| 90 | Cash cost to achieve, % of run-rate cost synergies | % | 65.0% | 65.0% | 0.0% | 0.0% | Disclosed: about 65% of run-rate cost synergies in each of the first two years, about $1,230m a year (joint proxy, pp.121 to 122); the announcement: $2.5bn in the first two years. Spent whether or not the synergies arrive. | |
| 91 | Integration capital spending | $m | 1,400.0 | Disclosed: about $1.4bn through 2029 under the Kenvue Integration Program (8-K of 2 November 2026, Item 2.05). | ||||
| 92 | Integration capital spending, % by year | % | 40.0% | 40.0% | 20.0% | 0.0% | Illustrative. The timing is not disclosed. | |
| 93 | Multiple put on the run-rate synergies, EV / EBITDA | x | 10.0x | Illustrative. For scale: the advisers’ peer tables put Kenvue at 9.9x and Kimberly-Clark at 11.2x 2026 EBITDA (joint proxy, Centerview’s analysis, p.106). | ||||
| 95 | Litigation (a what-if, not an estimate) | |||||||
| 96 | Litigation amount to test, after tax | $m | - | Illustrative control, nil by default. Kenvue says it cannot estimate the likelihood or size of liability for the acetaminophen or talc claims (10-Q for the third quarter of 2026, note 13). Paid in FY2027E and funded with debt. | ||||
| 97 | Net leverage target | x | 2.0x | Disclosed: approximately 2.0x net debt to EBITDA within 24 months of completion (investor presentation, 3 November 2025). | ||||
Select a cell to see its row, its schedule and the type of cell. Font colours: blue for inputs, black for formulas, green for links to other sheets. Scroll sideways to see every period.
Download
Kimberly-Clark and Kenvue merger model: the workbook
An Excel workbook with working formulas, no macros and no external links: the same model you can work with on this page.
- Browse without an accountPreview every model online, sheet by sheet, with its outputs and checks.
- Free accountWork with every model online: change the inputs, switch the case, see every formula. And every starter workbook, with its key schedules left blank to build.
- L3VLUP Plus$4.99/monthEverything in Free, and one worked model each billing month as an Excel file: every schedule built, formulas live, checks at zero, yours to keep.
- L3VLUP Pro$25/monthEverything in Plus, every worked model in the library, and the Pro applications.
- The worked model
- 11 sheets and 355 live formulas, all 10 schedules built and linked, every check reading zero. Change an input in Excel and the whole model moves.
- The starter
- The same inputs and layout with the pro forma EPS: accretion and dilution left blank for you to build, each blank cell marked. The worked model is its answer.
What the base case says
- Offer value per Kenvue share
- 21.01
- Kimberly-Clark holders’ ownership
- 54.2%
- Accretion / (dilution), FY2027E
- 0.4%
- Accretion / (dilution), FY2028E
- 10.5%
- Net debt / EBITDA, FY2028E
- 2.0x
- Left for Kimberly-Clark’s holders
- $2,561.0m
Read from the workbook as served, every input at its default. Periods: FY2027E, FY2028E, FY2029E, FY2030E. Built from the deal’s SEC filings, cited on the Sources sheet: the merger agreement and announcement, the joint proxy statement/prospectus with both companies’ projections and the synergy projections, the financing and completion reports, and both companies’ annual and quarterly reports. The rates the filings do not give, the timing read into the synergy profile, the multiple put on the synergies and any litigation amount are illustrative inputs, labelled, and move with whatever you type in.
What changes the answer
Every figure below is the workbook recalculated by its own formulas: the cases it carries, each key assumption moved a tenth either way, and the sensitivity grids from its own sheets. Nothing is estimated outside the model.
The cases, side by side
The scenario switch on the Assumptions sheet, set to each option in turn. Every check in the workbook reads zero in every case.
| Output | Baseas shipped | Downside | Upside |
|---|---|---|---|
| Offer value per Kenvue share | 21.01 | 21.01 | 21.01 |
| Kimberly-Clark holders’ ownership | 54.2% | 54.2% | 54.2% |
| Accretion / (dilution), FY2027E | 0.4% | -13.6%-14.0 pts | 7.6%+7.1 pts |
| Accretion / (dilution), FY2028E | 10.5% | -9.1%-19.7 pts | 20.5%+9.9 pts |
| Net debt / EBITDA, FY2028E | 2.0x | 2.5x+0.5x | 1.8x-0.2x |
| Left for Kimberly-Clark’s holders | $2,561.0m | $-3,154.3m-$5,715.3m | $2,561.0m |
What each case assumes
| Revenue, selected scenario | 15,678.0 | 15,678.0 | 15,913.0 |
|---|---|---|---|
| Adjusted EBITDA, selected scenario | 3,414.0 | 3,414.0 | 3,852.0 |
| Unlevered free cash flow, selected scenario | 2,186.0 | 2,186.0 | 2,515.0 |
| Cost synergies, % of run-rate, selected scenario | 40.0% | 0.0% | 40.0% |
| Growth synergies, % of run-rate, selected scenario | 25.0% | 0.0% | 25.0% |
| Synergies realised, selected scenario | 100.0% | 50.0% | 100.0% |
The first period of each assumption row the switch sets directly, in the order of the columns above.
What moves accretion or dilution most
Accretion / (dilution), FY2028E is 10.5% in the base case. Each bar moves one assumption 10% below and 10% above its own value, with everything else held, and shows where the output lands.
Adjusted EBITDA (kimberly-clark standalone projections)
10% lower: 18.6%10% higher: 4.3%
Kimberly-Clark shares delivered to Kenvue holders
10% lower: 16.3%10% higher: 5.3%
Adjusted EBITDA (kenvue projections)
10% lower: 5.2%10% higher: 15.9%
Kimberly-Clark diluted shares
10% lower: 5.3%10% higher: 15.2%
Synergies realised (synergies)
10% lower: 7.9%10% higher: 13.2%
Cost synergies (synergies)
10% lower: 8.1%10% higher: 13.0%
The sensitivity grids, as heatmaps
Accretion / (dilution): synergy realisation by year
| Synergies realised, % of disclosed ↓ / Year → | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| 50.0% | -6.6% | -2.2% | 3.9% | 8.1% |
| 75.0% | -3.1% | 4.2% | 11.8% | 15.9% |
| 100.0% | 0.4% | 10.5% | 19.6% | 23.7% |
| 125.0% | 3.9% | 16.9% | 27.5% | 31.6% |
| 150.0% | 7.4% | 23.3% | 35.4% | 39.4% |
Value left for Kimberly-Clark’s holders ($m): synergy multiple by realisation
| Multiple on run-rate synergies ↓ / Synergies realised, % of disclosed → | 50.0% | 75.0% | 100.0% | 125.0% | 150.0% |
|---|---|---|---|---|---|
| 6.0x | (5,440.4) | (3,725.8) | (2,011.2) | (296.6) | 1,418.0 |
| 8.0x | (4,297.4) | (2,011.2) | 274.9 | 2,561.0 | 4,847.1 |
| 10.0x | (3,154.3) | (296.6) | 2,561.0 | 5,418.7 | 8,276.3 |
| 12.0x | (2,011.2) | 1,418.0 | 4,847.1 | 8,276.3 | 11,705.5 |
| 14.0x | (868.2) | 3,132.5 | 7,133.3 | 11,134.0 | 15,134.7 |
Presenting these figures? In Deck Studio a slide can carry any output above, with the case and the cell printed as its source.Open Deck Studio
What this model is
A transaction model of Kimberly-Clark’s acquisition of Kenvue: $3.50 in cash and 0.14625 of a Kimberly-Clark share for each Kenvue share, announced on 3 November 2025 and completed on 2 November 2026.
It prices the offer as the announcement did, issues the shares the completion report gives, funds the cash with the notes, commercial paper and cash the filings describe, and runs both companies’ disclosed projections with the disclosed synergies through FY2030E: earnings per share against Kimberly-Clark standalone, net debt against the 2.0x target, and the synergy value against the premium.
Uses: reading a stock-and-cash merger from its filings; seeing how much of the earnings case and the value case rests on the synergies; and testing what a lower realisation, a different view of Kenvue or a litigation amount would do.
Seats: Investment banking, Equity research and hedge funds, Private equity.
Careers that do this work: investment banking, private equity, growth equity, corp dev / m&a, venture capital.
How the schedules connect
Every row in the workbook is tagged with the schedule it belongs to; the inspector above shows the tag when you click a row. These are the schedules this model is made of and where each one lives.
Purchase price and consideration
Offer, premium, mix, new shares, exchange ratio
Assumptions, rows 9–18 · Assumptions, rows 21–23 · Offer & Ownership, rows 5–9 · Offer & Ownership, rows 18–26
Enterprise value to equity value
Debt off, cash on, per share
Assumptions, rows 96–97 · Offer & Ownership, rows 12–15 · Value, rows 11–18
Contribution analysis
What each side brings against what it owns
Offer & Ownership, rows 29–31
Sources and uses
What the deal costs and who funds it
Assumptions, rows 26–41 · Sources & Uses, rows 5–8 · Sources & Uses, rows 11–17
Debt schedule
Tranches, interest, amortisation and the sweep
Assumptions, rows 44–50 · Sources & Uses, rows 20–24 · Pro Forma EPS, rows 21–22 · Leverage, rows 6–12 · Leverage, rows 15–17
Tax
Tax on profit, and tax on operating profit
Assumptions, rows 53–57 · Assumptions, row 60 · Pro Forma EPS, row 25
Synergies
Run-rate, phase-in, after tax
Assumptions, rows 79–93 · Synergies, rows 6–11 · Synergies, rows 14–15 · Pro Forma EPS, row 20 · Pro Forma EPS, rows 36–41 · Value, rows 5–8 · Value, rows 21–24
Purchase accounting
The write-up that amortises
Assumptions, rows 58–59 · Pro Forma EPS, row 23
Pro forma EPS: accretion and dilution
Standalone to pro forma, per share
Assumptions, rows 63–65 · Assumptions, rows 68–76 · Pro Forma EPS, rows 6–11 · Pro Forma EPS, rows 14–17 · Pro Forma EPS, rows 24–26 · Pro Forma EPS, rows 29–33 · Pro Forma EPS, rows 44–48
Sensitivity tables
Two assumptions at once, without a data table
Sensitivity, rows 5–6 · Sensitivity, rows 9–14 · Sensitivity, rows 17–25
What you should be able to explain
- Why a fixed exchange ratio fixes the number of new shares and leaves the value of the offer floating with the buyer’s price, and what that does to the premium the target’s holders receive.
- How accretion is built: each company’s standalone earnings, the synergies, the interest on the funding and the purchase accounting, over a share count that grows by the shares issued.
- Why accretion is not value: a deal can lift earnings per share in its second year and still leave the buyer’s holders little once the premium is set against what the synergies are worth.
- How the holders of a stock deal share the synergies: the target’s holders keep the premium and their part of what the synergies add beyond it, the buyer’s holders the rest, by ownership.
- How a litigation risk the filings cannot size is handled fairly: what the documents disclose, a material adverse effect definition that leaves it with the buyer, and a what-if amount rather than a forecast.
What a reviewer looks for
- Quoting the $48.7bn enterprise value as the cash paid. More than 80% of the consideration was Kimberly-Clark shares; the cash was about $6.7bn.
- Measuring the premium on one price only. On Kenvue’s close of 31 October 2025 it is 46.2%; on the 90-day average it is about 15%, because the shares had fallen after the acetaminophen reports.
- Counting the synergies at their run-rate from the first year. The disclosed profile reaches the cost run-rate in the third year, and the $2.5bn of cost to achieve falls in the first two.
- Reading accretion in the second year as proof of value. Without the synergies the deal dilutes Kimberly-Clark’s earnings per share in every year of the base case.
- Treating the litigation as a number the filings give. Kenvue says it cannot estimate the likelihood or size of the claims; any amount in the model is a what-if you choose.
Conventions this workbook uses
Stated on the cover sheet too. A model is only as trustworthy as the decisions it tells you it made.
- Disclosed figures are inputs with their source on the Sources sheet. Inputs the filings do not give are labelled illustrative in their notes: the rate on commercial paper and on any change in net debt, the timing of integration capital, the dividend held flat, the multiple put on the synergies, the downside case and the litigation amount.
- The offer is fixed in shares and cash: 0.14625 of a Kimberly-Clark share and $3.50 for each Kenvue share. The number of new shares is the 281.1 million the completion report gives; their value depends on the Kimberly-Clark price chosen, by default $119.71, the close on which the announcement was struck.
- FY2027E to FY2030E are the first four full years after completion. Both companies’ projections are the joint proxy’s, by fiscal year. The synergy projections’ profile is read as years after completion; the joint proxy tables them from fiscal 2026E on a completion not later than the second half of 2026.
- Earnings per share are adjusted: the cash cost to achieve the synergies is kept out of earnings and counted in cash and leverage. Amortisation of the acquired intangibles is included unless the Assumptions sheet excludes it. Kenvue’s own past amortisation is replaced by it.
- Standalone earnings are rebuilt from each projection’s adjusted EBITDA with depreciation, interest and tax at their FY2025 levels. Converted equity awards and buybacks are not modelled; the share count is held flat.
- Kenvue’s debt is assumed, so it is in combined net debt but not in sources and uses. The notes carry their coupons; commercial paper and cash used carry illustrative rates; interest on net debt above or below the level at completion is charged at an illustrative marginal rate.
- The value split works in market value at the prices chosen: net synergy value less the premium is what the merger adds for the two sets of holders together, and each keeps a share by its ownership of the combined company. Kenvue’s holders also keep the premium. Each standalone business is taken at its market price on the reference date, so a different view of Kenvue’s plan moves earnings and leverage, not the value split.
- The litigation control is an amount you set, nil by default, paid in FY2027E and funded with debt. It is a what-if: the filings give no estimate, and Kenvue says it cannot make one.
Build it yourself
The starter workbook
The earnings per share build has been cleared: both companies’ standalone net income, the deal adjustments, pro forma net income and shares, accretion, the synergies a year needs for no dilution and the bridge from standalone to pro forma. Rebuild them from the Assumptions, the Synergies and the Sources & Uses sheets. The Checks sheet shows when the bridge and the accretion grid tie to your result.
Blanks: Pro forma EPS: accretion and dilution. Download it beside the worked model.
Finished? Audit a model you built for errors, hardcodes and checks that do not tie, in your browser.
The path around this model
Understand it, drill it, read the build, then apply it to a real company.
Build · Lab · ~8 min
Accretion / Dilution Animator
Call a deal accretive or dilutive from P/E, premium and financing mix before you open a model.
Read · Guide · 14 min
How to Build a Merger Model: Purchase Accounting, Financing and Accretion
Read · Guide · 8 min
M&A Interview Questions: Accretion/Dilution and Beyond
Read · Guide · 7 min
Enterprise Value vs. Equity Value, Once and For All
Apply · Skill
Accretion and Dilution
Show what the deal does to the acquirer’s earnings per share.
Apply · Skill
Model Audit
Find the errors in a financial model before someone senior does.
Vocabulary: Merger Model, Accretion / Dilution, Synergies, Control Premium, Purchase Price Allocation (PPA), Exchange Offer, Break Fee, Fairness Opinion, Net Debt.
Questions about this model
How much of this model is disclosed and how much is assumed?
Disclosed: the cash and the exchange ratio, the prices the announcement used, the share counts at signing and completion, the notes and commercial paper that funded the cash, both balance sheets, both companies’ projections to 2030 (Kenvue in two versions, its own and Kimberly-Clark’s adjusted one), the synergy projections and their cost to achieve, the preliminary purchase accounting and the leverage target. Assumed, and labelled: the rates on commercial paper and on later changes in net debt, depreciation, interest and tax held at their 2025 levels, the dividend held flat, the timing of the integration capital, the downside case, the multiple put on the synergies and any litigation amount.
Is the deal accretive?
In the base case, on the page’s assumptions, earnings per share are roughly unchanged in FY2027E and about 10.5% higher in FY2028E, as the synergies build. Without the synergies the deal dilutes earnings per share in every year, so the answer rests on them. The announcement said only that it expected the deal to be accretive to adjusted earnings per share by year 2. These are conditional figures, not the combined company’s results.
What does the litigation control do?
It lets you test an amount, nil by default. The amount is paid in FY2027E, funded with debt, adds to net debt and interest and comes off the value left after the premium. The filings disclose the claims (the acetaminophen cases remanded by the Second Circuit in July 2026, the Texas case under appeal, and talc claims outside the United States and Canada that Kenvue keeps), but Kenvue says it cannot estimate the likelihood or size of any liability, so the model carries no estimate of its own.
Why are there two versions of Kenvue’s projections?
Because the joint proxy discloses both. Kenvue’s management prepared its own plan; Kimberly-Clark’s management adjusted it for slower growth, more marketing and research spending and later savings, and that version is what Kimberly-Clark’s advisers used. The base case uses Kimberly-Clark’s version; the upside uses Kenvue’s own.
Related models
M&A and private equity · Core
Merger model: accretion and dilution
Is the deal accretive, and what would break even
M&A and private equity · Advanced
Purchase price allocation model
Goodwill, write-ups, deferred tax, stock vs asset deal
M&A and private equity · Advanced
Merger arbitrage model: deal spread, break risk and position size
Deal spread, the hedge, break risk and position size
What assumption would you challenge?
Every model rests on a few judgements. Ask how one works, or say which input you would set differently and why.
No questions yet. Ask the first.